Dimensional Fund Advisors LP Corvus Pharmaceuticals, Inc. Transaction History

Dimensional Fund Advisors LP

$403 Billion
Q3 2024

A detailed history of Dimensional Fund Advisors LP transactions in Corvus Pharmaceuticals, Inc. stock. As of the latest transaction made, Dimensional Fund Advisors LP holds 11,924 shares of CRVS stock, worth $62,124. This represents 0.0% of its overall portfolio holdings.

Number of Shares

11,924

Previous 11,924 -0.0%

Holding current value

$62,124

Previous $21,000 195.24%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 07, 2024	SELL	$1.08 - $1.92 $3,203 - $5,694	-2,966 Reduced 19.92%	11,924 $20,000
Q3 2023 Nov 09, 2023	SELL	$1.41 - $2.97 $60,943 - $128,369	-43,222 Reduced 74.38%	14,890 $21,000
Q2 2023 Aug 09, 2023	BUY	$1.0 - $3.86 $58,112 - $224,312	58,112 New	58,112 $133,000
Q4 2022 Feb 09, 2023	SELL	$0.74 - $1.04 $8,578 - $12,055	-11,592 Reduced 31.29%	25,459 $21,000
Q3 2022 Nov 10, 2022	SELL	$0.71 - $1.17 $138,993 - $229,046	-195,766 Reduced 84.09%	37,051 $30,000
Q2 2022 Aug 12, 2022	SELL	$0.87 - $2.03 $162,101 - $378,235	-186,323 Reduced 44.45%	232,817 $231,000
Q1 2022 May 13, 2022	SELL	$1.46 - $2.48 $81,673 - $138,733	-55,941 Reduced 11.78%	419,140 $687,000
Q4 2021 Feb 09, 2022	BUY	$2.34 - $5.31 $690,409 - $1.57 Million	295,047 Added 163.88%	475,081 $1.15 Million
Q3 2021 Nov 12, 2021	SELL	$1.89 - $8.53 $407,852 - $1.84 Million	-215,795 Reduced 54.52%	180,034 $874,000
Q2 2021 Aug 12, 2021	SELL	$2.46 - $3.14 $51,217 - $65,374	-20,820 Reduced 5.0%	395,829 $1.06 Million
Q1 2021 May 14, 2021	SELL	$2.86 - $4.77 $55,938 - $93,296	-19,559 Reduced 4.48%	416,649 $1.28 Million
Q4 2020 Feb 25, 2021	BUY	$3.56 - $4.86 $1.55 Million - $2.12 Million	436,208 New	436,208 $1.55 Million

Others Institutions Holding CRVS

# of Institutions

Shares Held

30.5M

Call Options Held

1.06M

Put Options Held

84.3K

View Full List

About Corvus Pharmaceuticals, Inc.

Ticker CRVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,553,500
Market Cap $243M
Description
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...

More about CRVS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Dimensional Fund Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on Dimensional Fund Advisors LP with notifications on news.

Account

Dimensional Fund Advisors LP Corvus Pharmaceuticals, Inc. Transaction History